Takeda Pharmaceuticals International has entered a new research collaboration to study the ability of Prana Biotechnology’s investigational movement disorders compound, PBT434, to slow down or prevent neurodegeneration of the gastrointestinal system of a patient with Parkinson's disease.

Prana Biotechnology was established to commercialise research into neurodegenerative diseases such as Alzheimer's, Huntington, and Parkinson.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

PBT434 is the first of a new generation of small molecules from the quinazolinone class of drugs that was particularly designed to block the accumulation and aggregation of alpha-synuclein.

One of the most significant non-motor features of Parkinson’s disease is the early presentation of severe and disabling impairment of gastrointestinal function, and results in the loss of neurons and their networks in the brain and in the gut.

"PBT434 is the first of a new generation of small molecules from the quinazolinone class of drugs that was particularly designed to block the accumulation and aggregation of alpha-synuclein."

Prana Biotechnology senior scientific consultant David Finkelstein said: “This early research is important because our major therapeutic objective is to treat these disabling symptoms and provide an early therapeutic intervention for both motor and non-motor Parkinsonian symptoms in patients which may significantly impact on the quality of life.”

See Also:

In a recent publication, the company revealed the results with PBT434 that demonstrated a significant reduction of alpha-synuclein in various pre-clinical models of the disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PBT434 can reduce the formation of toxic alpha-synuclein fibrils and aggregates, rescue neurons burdened by such toxic forms of alpha-synuclein and restore motor function in animal models.

Later this year, the company is expected to start human testing of the compound in a Phase I trial.